PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Operating Lease, Payments in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Provectus Biopharmaceuticals, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q1 2019 to Q1 2024.
  • Provectus Biopharmaceuticals, Inc. Operating Lease, Payments for the quarter ending March 31, 2024 was $11.6K, a 8.36% increase year-over-year.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2023 was $44.4K, a 29.4% decline from 2022.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2022 was $62.9K, a 23.9% decline from 2021.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2021 was $82.7K, a 9.75% decline from 2020.
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $11.6K +$897 +8.36% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q1 2023 $10.7K -$13.1K -55% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2022 $23.8K $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $23.8K +$1.39K +6.19% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 $22.4K +$440 +2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q1 2019 $22K Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.